25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Zevra Therapeutics Inc.
Buy, Hold or Sell?

Let's analyze Zevra together

I guess you are interested in Zevra Therapeutics Inc.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Zevra Therapeutics Inc.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Zevra Therapeutics Inc.

I send you an email if I find something interesting about Zevra Therapeutics Inc..

1. Quick Overview

1.1. Quick analysis of Zevra (30 sec.)










1.2. What can you expect buying and holding a share of Zevra? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.31
Expected worth in 1 year
$1.36
How sure are you?
28.2%

+ What do you gain per year?

Total Gains per Share
$0.06
Return On Investment
0.6%

For what price can you sell your share?

Current Price per Share
$9.59
Expected price per share
$6.61 - $
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Zevra (5 min.)




Live pricePrice per Share (EOD)
$9.59
Intrinsic Value Per Share
$-36.68 - $-8.99
Total Value Per Share
$-35.37 - $-7.69

2.2. Growth of Zevra (5 min.)




Is Zevra growing?

Current yearPrevious yearGrowGrow %
How rich?$69.7m$73.2m-$22.9m-45.6%

How much money is Zevra making?

Current yearPrevious yearGrowGrow %
Making money-$23.2m-$9.9m-$13.2m-57.1%
Net Profit Margin-610.8%-335.7%--

How much money comes from the company's main activities?

2.3. Financial Health of Zevra (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Zevra?

Welcome investor! Zevra's management wants to use your money to grow the business. In return you get a share of Zevra.

First you should know what it really means to hold a share of Zevra. And how you can make/lose money.

Speculation

The Price per Share of Zevra is $9.585. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Zevra.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Zevra, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.31. Based on the TTM, the Book Value Change Per Share is $0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Zevra.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.62-6.5%-0.44-4.5%-0.19-2.0%-0.17-1.7%-0.18-1.8%
Usd Book Value Change Per Share0.707.3%0.010.1%-0.12-1.3%0.141.4%0.030.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.707.3%0.010.1%-0.12-1.3%0.141.4%0.030.4%
Usd Price Per Share6.94-5.88-5.00-5.58-5.93-
Price to Earnings Ratio-2.79--3.58--7.75--11.63--10.23-
Price-to-Total Gains Ratio9.93--7.56--98.70--12.99--38.29-
Price to Book Ratio5.31-6.57-3.69-2.68-14.08-
Price-to-Total Gains Ratio9.93--7.56--98.70--12.99--38.29-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.585
Number of shares104
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.14
Usd Total Gains Per Share0.010.14
Gains per Quarter (104 shares)1.4914.40
Gains per Year (104 shares)5.9857.59
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
106-405848
201220115106
301880173164
4024140230222
5030200288280
6036260346338
7042320403396
8048380461454
9054440518512
10060500576570

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.03.00.00.0%0.011.00.00.0%2.017.00.010.5%4.035.00.010.3%4.039.00.09.3%
Book Value Change Per Share1.02.00.033.3%1.010.00.09.1%7.012.00.036.8%11.028.00.028.2%12.029.02.027.9%
Dividend per Share0.00.03.00.0%0.00.011.00.0%0.00.019.00.0%0.00.039.00.0%0.00.043.00.0%
Total Gains per Share1.02.00.033.3%1.010.00.09.1%7.012.00.036.8%11.028.00.028.2%12.029.02.027.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Zevra Therapeutics Inc. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.6990.014+4764%-0.123+118%0.138+405%0.034+1926%
Book Value Per Share--1.3070.943+39%1.373-5%0.885+48%0.019+6665%
Current Ratio--2.8842.329+24%6.647-57%10.611-73%8.504-66%
Debt To Asset Ratio--0.6360.696-9%0.363+75%2.137-70%2.494-75%
Debt To Equity Ratio--1.7452.430-28%0.610+186%0.553+215%8.769-80%
Dividend Per Share----0%-0%-0%-0%
Eps---0.622-0.436-30%-0.187-70%-0.167-73%-0.177-72%
Free Cash Flow Per Share---0.340-0.334-2%-0.103-70%-0.083-75%-0.120-65%
Free Cash Flow To Equity Per Share--0.8740.174+401%0.005+16762%0.142+515%0.063+1277%
Gross Profit Margin--1.0001.184-16%1.0000%1.029-3%1.020-2%
Intrinsic Value_10Y_max---8.994--------
Intrinsic Value_10Y_min---36.676--------
Intrinsic Value_1Y_max---0.543--------
Intrinsic Value_1Y_min---1.144--------
Intrinsic Value_3Y_max---1.904--------
Intrinsic Value_3Y_min---5.651--------
Intrinsic Value_5Y_max---3.595--------
Intrinsic Value_5Y_min---12.548--------
Market Cap511608001.500+28%370428746.000313850292.000+18%267012939.750+39%298051025.600+24%316649105.218+17%
Net Profit Margin---8.992-6.108-32%-3.357-63%-3.470-61%-1.684-81%
Operating Margin----2.8830%-1.3850%-1.5730%-0.7590%
Operating Ratio--7.9727.101+12%2.739+191%3.152+153%1.554+413%
Pb Ratio7.333+28%5.3096.568-19%3.688+44%2.681+98%14.081-62%
Pe Ratio-3.850-38%-2.787-3.575+28%-7.748+178%-11.629+317%-10.226+267%
Price Per Share9.585+28%6.9405.880+18%5.003+39%5.584+24%5.932+17%
Price To Free Cash Flow Ratio-7.050-38%-5.105-4.438-13%-13.209+159%-25.021+390%-19.094+274%
Price To Total Gains Ratio13.719+28%9.933-7.557+176%-98.696+1094%-12.988+231%-38.286+485%
Quick Ratio--1.7931.915-6%8.546-79%10.890-84%10.058-82%
Return On Assets---0.173-0.140-19%-0.084-51%-0.157-10%-0.228+32%
Return On Equity---0.476-0.477+0%-0.138-71%-0.127-73%0.382-225%
Total Gains Per Share--0.6990.014+4764%-0.123+118%0.138+405%0.034+1926%
Usd Book Value--69770000.00050355333.333+39%73295000.000-5%47253052.632+48%1031341.333+6665%
Usd Book Value Change Per Share--0.6990.014+4764%-0.123+118%0.138+405%0.034+1926%
Usd Book Value Per Share--1.3070.943+39%1.373-5%0.885+48%0.019+6665%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.622-0.436-30%-0.187-70%-0.167-73%-0.177-72%
Usd Free Cash Flow---18141000.000-17805000.000-2%-5524250.000-70%-4450736.842-75%-6424174.590-65%
Usd Free Cash Flow Per Share---0.340-0.334-2%-0.103-70%-0.083-75%-0.120-65%
Usd Free Cash Flow To Equity Per Share--0.8740.174+401%0.005+16762%0.142+515%0.063+1277%
Usd Market Cap511608001.500+28%370428746.000313850292.000+18%267012939.750+39%298051025.600+24%316649105.218+17%
Usd Price Per Share9.585+28%6.9405.880+18%5.003+39%5.584+24%5.932+17%
Usd Profit---33225000.000-23257333.333-30%-9979250.000-70%-8925684.211-73%-9445199.000-72%
Usd Revenue--3695000.0003856333.333-4%4140750.000-11%4188684.211-12%2334564.103+58%
Usd Total Gains Per Share--0.6990.014+4764%-0.123+118%0.138+405%0.034+1926%
 EOD+6 -2MRQTTM+19 -14YOY+10 -225Y+14 -1910Y+18 -15

3.3 Fundamental Score

Let's check the fundamental score of Zevra Therapeutics Inc. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.850
Price to Book Ratio (EOD)Between0-17.333
Net Profit Margin (MRQ)Greater than0-8.992
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.793
Current Ratio (MRQ)Greater than12.884
Debt to Asset Ratio (MRQ)Less than10.636
Debt to Equity Ratio (MRQ)Less than11.745
Return on Equity (MRQ)Greater than0.15-0.476
Return on Assets (MRQ)Greater than0.05-0.173
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Zevra Therapeutics Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5067.475
Ma 20Greater thanMa 508.708
Ma 50Greater thanMa 1008.190
Ma 100Greater thanMa 2007.464
OpenGreater thanClose9.240
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Zevra Therapeutics Inc.

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Fundamental data was last updated by Penke on 2024-11-20 01:04:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Zevra earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Zevra to the Biotechnology industry mean.
  • A Net Profit Margin of -899.2% means that $-8.99 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Zevra Therapeutics Inc.:

  • The MRQ is -899.2%. The company is making a huge loss. -2
  • The TTM is -610.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-899.2%TTM-610.8%-288.4%
TTM-610.8%YOY-335.7%-275.1%
TTM-610.8%5Y-347.0%-263.8%
5Y-347.0%10Y-168.4%-178.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-899.2%-120.2%-779.0%
TTM-610.8%-210.7%-400.1%
YOY-335.7%-219.8%-115.9%
5Y-347.0%-348.0%+1.0%
10Y-168.4%-473.2%+304.8%
4.3.1.2. Return on Assets

Shows how efficient Zevra is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Zevra to the Biotechnology industry mean.
  • -17.3% Return on Assets means that Zevra generated $-0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Zevra Therapeutics Inc.:

  • The MRQ is -17.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -14.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.3%TTM-14.0%-3.3%
TTM-14.0%YOY-8.4%-5.6%
TTM-14.0%5Y-15.7%+1.6%
5Y-15.7%10Y-22.8%+7.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.3%-11.0%-6.3%
TTM-14.0%-11.8%-2.2%
YOY-8.4%-11.3%+2.9%
5Y-15.7%-12.6%-3.1%
10Y-22.8%-14.3%-8.5%
4.3.1.3. Return on Equity

Shows how efficient Zevra is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Zevra to the Biotechnology industry mean.
  • -47.6% Return on Equity means Zevra generated $-0.48 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Zevra Therapeutics Inc.:

  • The MRQ is -47.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -47.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-47.6%TTM-47.7%+0.1%
TTM-47.7%YOY-13.8%-33.9%
TTM-47.7%5Y-12.7%-34.9%
5Y-12.7%10Y38.2%-50.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-47.6%-14.1%-33.5%
TTM-47.7%-15.8%-31.9%
YOY-13.8%-13.9%+0.1%
5Y-12.7%-18.5%+5.8%
10Y38.2%-19.2%+57.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Zevra Therapeutics Inc..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Zevra is operating .

  • Measures how much profit Zevra makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Zevra to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Zevra Therapeutics Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-288.3%+288.3%
TTM-288.3%YOY-138.5%-149.8%
TTM-288.3%5Y-157.3%-131.0%
5Y-157.3%10Y-75.9%-81.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--267.8%+267.8%
TTM-288.3%-313.4%+25.1%
YOY-138.5%-224.0%+85.5%
5Y-157.3%-385.5%+228.2%
10Y-75.9%-498.7%+422.8%
4.3.2.2. Operating Ratio

Measures how efficient Zevra is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 7.97 means that the operating costs are $7.97 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Zevra Therapeutics Inc.:

  • The MRQ is 7.972. The company is inefficient in keeping operating costs low. -1
  • The TTM is 7.101. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ7.972TTM7.101+0.871
TTM7.101YOY2.739+4.362
TTM7.1015Y3.152+3.948
5Y3.15210Y1.554+1.598
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.9722.631+5.341
TTM7.1013.412+3.689
YOY2.7393.299-0.560
5Y3.1524.788-1.636
10Y1.5546.538-4.984
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Zevra Therapeutics Inc..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Zevra is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.88 means the company has $2.88 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Zevra Therapeutics Inc.:

  • The MRQ is 2.884. The company is able to pay all its short-term debts. +1
  • The TTM is 2.329. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.884TTM2.329+0.555
TTM2.329YOY6.647-4.318
TTM2.3295Y10.611-8.282
5Y10.61110Y8.504+2.107
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8843.690-0.806
TTM2.3293.875-1.546
YOY6.6474.684+1.963
5Y10.6115.946+4.665
10Y8.5046.274+2.230
4.4.3.2. Quick Ratio

Measures if Zevra is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Zevra to the Biotechnology industry mean.
  • A Quick Ratio of 1.79 means the company can pay off $1.79 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Zevra Therapeutics Inc.:

  • The MRQ is 1.793. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.915. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.793TTM1.915-0.122
TTM1.915YOY8.546-6.631
TTM1.9155Y10.890-8.975
5Y10.89010Y10.058+0.832
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7933.122-1.329
TTM1.9153.451-1.536
YOY8.5464.498+4.048
5Y10.8905.922+4.968
10Y10.0586.414+3.644
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Zevra Therapeutics Inc..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Zevra assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Zevra to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.64 means that Zevra assets are financed with 63.6% credit (debt) and the remaining percentage (100% - 63.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Zevra Therapeutics Inc.:

  • The MRQ is 0.636. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.696. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.636TTM0.696-0.060
TTM0.696YOY0.363+0.333
TTM0.6965Y2.137-1.441
5Y2.13710Y2.494-0.357
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6360.353+0.283
TTM0.6960.350+0.346
YOY0.3630.311+0.052
5Y2.1370.367+1.770
10Y2.4940.382+2.112
4.5.4.2. Debt to Equity Ratio

Measures if Zevra is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Zevra to the Biotechnology industry mean.
  • A Debt to Equity ratio of 174.5% means that company has $1.75 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Zevra Therapeutics Inc.:

  • The MRQ is 1.745. The company is just able to pay all its debts with equity.
  • The TTM is 2.430. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.745TTM2.430-0.685
TTM2.430YOY0.610+1.820
TTM2.4305Y0.553+1.877
5Y0.55310Y8.769-8.216
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7450.393+1.352
TTM2.4300.435+1.995
YOY0.6100.378+0.232
5Y0.5530.451+0.102
10Y8.7690.493+8.276
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Zevra generates.

  • Above 15 is considered overpriced but always compare Zevra to the Biotechnology industry mean.
  • A PE ratio of -2.79 means the investor is paying $-2.79 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Zevra Therapeutics Inc.:

  • The EOD is -3.850. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.787. Based on the earnings, the company is expensive. -2
  • The TTM is -3.575. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.850MRQ-2.787-1.062
MRQ-2.787TTM-3.575+0.788
TTM-3.575YOY-7.748+4.173
TTM-3.5755Y-11.629+8.054
5Y-11.62910Y-10.226-1.403
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.850-2.126-1.724
MRQ-2.787-2.454-0.333
TTM-3.575-3.147-0.428
YOY-7.748-3.335-4.413
5Y-11.629-6.070-5.559
10Y-10.226-6.597-3.629
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Zevra Therapeutics Inc.:

  • The EOD is -7.050. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.105. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.438. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.050MRQ-5.105-1.946
MRQ-5.105TTM-4.438-0.667
TTM-4.438YOY-13.209+8.771
TTM-4.4385Y-25.021+20.583
5Y-25.02110Y-19.094-5.927
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.050-2.981-4.069
MRQ-5.105-3.363-1.742
TTM-4.438-3.667-0.771
YOY-13.209-4.535-8.674
5Y-25.021-8.343-16.678
10Y-19.094-9.276-9.818
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Zevra is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.31 means the investor is paying $5.31 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Zevra Therapeutics Inc.:

  • The EOD is 7.333. Based on the equity, the company is overpriced. -1
  • The MRQ is 5.309. Based on the equity, the company is overpriced. -1
  • The TTM is 6.568. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD7.333MRQ5.309+2.023
MRQ5.309TTM6.568-1.259
TTM6.568YOY3.688+2.879
TTM6.5685Y2.681+3.887
5Y2.68110Y14.081-11.400
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.3331.863+5.470
MRQ5.3092.028+3.281
TTM6.5682.339+4.229
YOY3.6882.391+1.297
5Y2.6813.666-0.985
10Y14.0814.360+9.721
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Zevra Therapeutics Inc..

4.8.3. Insider Transactions

Insiders are holding 6.616% of the shares of Zevra Therapeutics Inc..

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-10-11Corey Michael WattonBUY5007.92
2024-07-17R. Laduane CliftonBUY20006.77
2024-07-16Thomas AndersonBUY100006.81
2024-07-12John B BodeBUY100005.87
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-06-302023-09-302024-03-312024-06-302024-09-30
Total Other Income Expense Net 131-71243,6703,7941463,940-9,859-5,919



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. All numbers in thousands.

Summary
Total Assets191,551
Total Liabilities121,781
Total Stockholder Equity69,770
 As reported
Total Liabilities 121,781
Total Stockholder Equity+ 69,770
Total Assets = 191,551

Assets

Total Assets191,551
Total Current Assets99,442
Long-term Assets92,109
Total Current Assets
Cash And Cash Equivalents 54,039
Net Receivables 7,790
Inventory 8,756
Other Current Assets 28,857
Total Current Assets  (as reported)99,442
Total Current Assets  (calculated)99,442
+/-0
Long-term Assets
Property Plant Equipment 1,427
Goodwill 4,701
Intangible Assets 70,608
Long-term Assets Other 9,268
Long-term Assets  (as reported)92,109
Long-term Assets  (calculated)86,004
+/- 6,105

Liabilities & Shareholders' Equity

Total Current Liabilities34,481
Long-term Liabilities87,300
Total Stockholder Equity69,770
Total Current Liabilities
Short-term Debt 540
Other Current Liabilities 33,941
Total Current Liabilities  (as reported)34,481
Total Current Liabilities  (calculated)34,481
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)87,300
Long-term Liabilities  (calculated)0
+/- 87,300
Total Stockholder Equity
Common Stock5
Retained Earnings -469,550
Accumulated Other Comprehensive Income -115
Other Stockholders Equity 539,430
Total Stockholder Equity (as reported)69,770
Total Stockholder Equity (calculated)69,770
+/-0
Other
Cash and Short Term Investments 54,039
Common Stock Shares Outstanding 47,809
Liabilities and Stockholders Equity 191,551
Net Debt 5,888
Net Working Capital 64,961
Short Long Term Debt Total 59,927



5.3. Balance Sheets Structured

All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-31
> Total Assets 
2,429
0
0
21,531
13,714
13,769
66,531
61,416
55,723
111,939
104,634
94,544
84,887
75,641
69,048
59,314
52,456
42,649
34,000
18,737
26,746
19,867
13,009
12,890
10,507
8,885
12,328
11,204
11,209
90,435
138,797
137,186
132,941
125,706
124,258
119,551
115,529
106,595
105,518
138,982
151,283
144,408
191,551
191,551144,408151,283138,982105,518106,595115,529119,551124,258125,706132,941137,186138,79790,43511,20911,20412,3288,88510,50712,89013,00919,86726,74618,73734,00042,64952,45659,31469,04875,64184,88794,544104,634111,93955,72361,41666,53113,76913,71421,531002,429
   > Total Current Assets 
2,040
1,969
0
19,092
10,278
10,322
64,822
59,616
54,078
111,387
84,568
65,261
74,357
63,018
55,364
50,198
46,996
39,079
30,909
16,737
23,721
15,311
8,640
8,684
6,634
5,511
9,065
8,144
8,382
87,729
136,181
134,630
115,056
105,780
87,435
85,133
93,023
104,280
103,427
137,013
62,890
60,891
99,442
99,44260,89162,890137,013103,427104,28093,02385,13387,435105,780115,056134,630136,18187,7298,3828,1449,0655,5116,6348,6848,64015,31123,72116,73730,90939,07946,99650,19855,36463,01874,35765,26184,568111,38754,07859,61664,82210,32210,27819,09201,9692,040
       Cash And Cash Equivalents 
1,969
-1,969
0
19,023
10,255
10,269
64,223
59,009
32,318
77,333
27,510
20,846
16,762
12,880
12,386
7,829
10,871
8,750
16,497
1,788
18,409
13,438
7,308
6,518
3,217
2,356
6,369
5,267
4,213
75,917
132,295
131,503
112,346
100,242
76,779
70,059
65,466
40,181
66,196
43,269
42,849
39,260
54,039
54,03939,26042,84943,26966,19640,18165,46670,05976,779100,242112,346131,503132,29575,9174,2135,2676,3692,3563,2176,5187,30813,43818,4091,78816,4978,75010,8717,82912,38612,88016,76220,84627,51077,33332,31859,00964,22310,26910,25519,0230-1,9691,969
       Short-term Investments 
0
3,937
0
0
0
0
0
0
19,002
33,668
55,134
42,679
51,003
48,243
41,107
37,412
31,358
25,873
11,702
11,239
3,260
0
0
0
0
0
0
0
0
0
0
0
0
1,338
4,199
5,832
17,381
55,103
21,175
40,157
9,868
9,998
0
09,9989,86840,15721,17555,10317,3815,8324,1991,3380000000000003,26011,23911,70225,87331,35837,41241,10748,24351,00342,67955,13433,66819,0020000003,9370
       Net Receivables 
0
0
0
0
22
0
0
0
2,375
0
0
0
5,003
0
0
2,503
2,081
1,511
0
0
140
0
0
1,638
1,865
2,265
2,093
2,202
2,579
11,308
1,888
1,619
1,528
3,320
2,820
6,583
8,299
7,822
14,033
51,926
8,305
8,947
7,790
7,7908,9478,30551,92614,0337,8228,2996,5832,8203,3201,5281,6191,88811,3082,5792,2022,0932,2651,8651,63800140001,5112,0812,503005,0030002,375000220000
       Other Current Assets 
71
0
0
69
0
53
599
607
2,758
386
824
636
489
795
771
1,354
1,384
1,845
1,610
2,610
1,688
1,873
1,332
528
1,552
890
603
675
203
395
1,998
1,508
252
880
3,637
2,659
1,300
1,174
2,023
1,661
11,736
12,684
28,857
28,85712,68411,7361,6612,0231,1741,3002,6593,6378802521,5081,9983952036756038901,5525281,3321,8731,6882,6101,6101,8451,3841,3547717954896368243862,758607599530690071
   > Long-term Assets 
389
-1,969
0
2,439
3,436
3,447
1,709
1,800
1,645
552
20,066
29,283
10,530
12,623
13,684
9,116
5,460
3,570
3,091
2,000
3,025
4,556
4,369
4,206
3,873
3,374
3,263
3,060
2,827
2,706
2,616
2,556
17,885
19,926
36,823
34,418
22,506
2,315
2,091
1,969
88,393
83,517
92,109
92,10983,51788,3931,9692,0912,31522,50634,41836,82319,92617,8852,5562,6162,7062,8273,0603,2633,3743,8734,2064,3694,5563,0252,0003,0913,5705,4609,11613,68412,62310,53029,28320,0665521,6451,8001,7093,4473,4362,4390-1,969389
       Property Plant Equipment 
380
0
0
342
352
354
352
386
403
443
1,105
1,456
1,970
2,201
2,148
2,086
2,004
1,924
1,841
1,817
1,753
3,473
3,331
3,190
3,008
2,661
2,550
2,436
2,389
2,269
2,179
2,117
2,025
1,925
2,069
1,920
1,782
1,642
1,492
1,340
1,781
1,589
1,427
1,4271,5891,7811,3401,4921,6421,7821,9202,0691,9252,0252,1172,1792,2692,3892,4362,5502,6613,0083,1903,3313,4731,7531,8171,8411,9242,0042,0862,1482,2011,9701,4561,10544340338635235435234200380
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,701
4,701
4,701
4,7014,7014,7010000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,422
17,564
33,535
31,463
20,000
0
0
0
0
0
0
00000020,00031,46333,53517,56415,42200000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
67,699
66,154
70,608
70,60866,15467,6990000000000000000000000000000000000000000
       Other Assets 
9
0
0
2,098
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,035
724
673
0
0
0
0
0
000006737241,03500000000000000000000000000000002,098009
> Total Liabilities 
7,749
0
0
23,558
38,015
68,120
63,076
67,162
65,844
123,421
104,301
104,346
103,583
105,480
108,325
107,414
109,972
122,332
117,545
114,082
93,312
94,703
94,556
83,510
84,963
77,560
75,191
73,531
77,621
6,184
8,134
5,449
5,823
4,207
25,025
25,757
29,722
35,191
37,019
71,512
102,465
111,930
121,781
121,781111,930102,46571,51237,01935,19129,72225,75725,0254,2075,8235,4498,1346,18477,62173,53175,19177,56084,96383,51094,55694,70393,312114,082117,545122,332109,972107,414108,325105,480103,583104,346104,301123,42165,84467,16263,07668,12038,01523,558007,749
   > Total Current Liabilities 
5,243
0
0
3,564
3,935
3,683
4,910
6,792
8,342
5,845
7,391
5,704
6,642
4,808
6,592
6,647
11,509
13,810
17,603
18,323
12,004
15,172
14,975
10,409
5,431
75,559
72,549
70,798
7,536
4,238
5,959
3,698
4,230
2,945
7,159
8,431
11,726
15,616
18,252
21,714
29,909
30,449
34,481
34,48130,44929,90921,71418,25215,61611,7268,4317,1592,9454,2303,6985,9594,2387,53670,79872,54975,5595,43110,40914,97515,17212,00418,32317,60313,81011,5096,6476,5924,8086,6425,7047,3915,8458,3426,7924,9103,6833,9353,564005,243
       Short-term Debt 
3,846
0
0
0
32
32
32
2,761
3,436
1,667
2,035
105
157
162
177
180
3,522
3,520
3,523
3,543
3,547
6,765
6,891
7,087
284
68,907
67,580
66,238
889
1,019
342
381
371
363
469
474
5,141
470
456
433
583
1,192
540
5401,1925834334564705,1414744693633713813421,01988966,23867,58068,9072847,0876,8916,7653,5473,5433,5233,5203,5221801771621571052,0351,6673,4362,7613232320003,846
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,655
0
0
0
0
0
0
0000004,655000000000000000000000000000000000000
       Accounts payable 
386
0
0
3,533
1,670
4,000
4,878
4,031
1,252
4,178
5,356
4,499
469
4,184
6,103
6,355
2,177
10,177
13,967
14,377
3,715
8,178
7,862
3,095
1,140
6,115
4,529
4,247
1,174
2,855
2,973
2,085
516
2,582
3,600
4,279
3,611
10,098
8,710
13,080
22,785
20,452
0
020,45222,78513,0808,71010,0983,6114,2793,6002,5825162,0852,9732,8551,1744,2474,5296,1151,1403,0957,8628,1783,71514,37713,96710,1772,1776,3556,1034,1844694,4995,3564,1781,2524,0314,8784,0001,6703,53300386
       Other Current Liabilities 
1,011
0
0
31
2,233
3,651
4,878
4,031
3,654
4,178
5,356
5,599
41
4,646
6,415
6,467
112
10,290
14,080
14,780
115
8,407
8,084
3,322
236
6,652
4,969
4,560
172
3,219
5,617
3,317
821
2,582
1,294
853
2,974
15,146
17,796
8,201
6,541
8,805
33,941
33,9418,8056,5418,20117,79615,1462,9748531,2942,5828213,3175,6173,2191724,5604,9696,6522363,3228,0848,40711514,78014,08010,2901126,4676,4154,646415,5995,3564,1783,6544,0314,8783,6512,23331001,011
   > Long-term Liabilities 
2,506
0
0
19,994
34,081
64,437
58,166
60,370
57,502
117,576
96,910
98,642
96,941
100,672
101,733
100,767
98,463
108,522
99,942
95,759
81,308
79,531
79,581
73,101
79,532
2,001
2,642
2,733
70,085
1,946
2,175
1,751
1,593
1,262
17,866
17,326
17,996
19,575
18,767
49,798
72,556
81,481
87,300
87,30081,48172,55649,79818,76719,57517,99617,32617,8661,2621,5931,7512,1751,94670,0852,7332,6422,00179,53273,10179,58179,53181,30895,75999,942108,52298,463100,767101,733100,67296,94198,64296,910117,57657,50260,37058,16664,43734,08119,994002,506
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,569
4,353
5,925
0
0
0
0
0
000005,9254,3533,56900000000000000000000000000000000000
> Total Stockholder Equity
-5,320
-5,320
0
-2,027
-24,302
-54,351
3,455
-5,746
-10,121
-11,482
333
-9,802
-18,696
-29,839
-39,277
-48,100
-57,516
-79,683
-83,545
-95,345
-66,566
-74,836
-81,547
-70,620
-74,456
-68,675
-62,863
-62,327
-66,412
84,251
130,663
131,737
127,118
121,499
99,233
93,794
85,807
71,404
68,499
67,470
48,818
32,478
69,770
69,77032,47848,81867,47068,49971,40485,80793,79499,233121,499127,118131,737130,66384,251-66,412-62,327-62,863-68,675-74,456-70,620-81,547-74,836-66,566-95,345-83,545-79,683-57,516-48,100-39,277-29,839-18,696-9,802333-11,482-10,121-5,7463,455-54,351-24,302-2,0270-5,320-5,320
   Common Stock
1,438
0
0
2
0
2
3
3
1
1
1
1
1
1
1
1
1
2
2
2
3
3
3
3
4
6
7
7
0
3
3
4
4
3
3
3
3
3
3
3
4
4
5
5443333333443307764333322211111111133202001,438
   Retained Earnings Total Equity0000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
-24,267
0
0
0
-42,790
0
-32,615
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
201
113
-63
-225
-220
141
421
-115
-115421141-220-225-63113201000000000000000000000000000-32,6150-42,790000-24,2670
   Capital Surplus 0000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
-24,267
0
1,606
-11,428
1,781
58,706
89,873
94,702
96,275
98,322
101,601
102,643
103,732
104,901
106,059
107,209
111,260
117,391
120,662
154,623
158,644
161,190
169,054
171,254
182,787
187,739
191,284
192,062
353,018
393,227
396,059
394,143
390,389
392,165
393,141
394,263
391,803
394,144
407,155
465,073
468,378
539,430
539,430468,378465,073407,155394,144391,803394,263393,141392,165390,389394,143396,059393,227353,018192,062191,284187,739182,787171,254169,054161,190158,644154,623120,662117,391111,260107,209106,059104,901103,732102,643101,60198,32296,27594,70289,87358,7061,781-11,4281,6060-24,2670



5.4. Balance Sheets

All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2023-12-31. All numbers in thousands.

Gross Profit (+$)
totalRevenue27,461
Cost of Revenue-2,945
Gross Profit24,51624,516
 
Operating Income (+$)
Gross Profit24,516
Operating Expense-74,120
Operating Income-49,604-49,604
 
Operating Expense (+$)
Research Development39,806
Selling General Administrative24,734
Selling And Marketing Expenses0
Operating Expense74,12064,540
 
Net Interest Income (+$)
Interest Income4,609
Interest Expense-1,501
Other Finance Cost-586
Net Interest Income3,694
 
Pretax Income (+$)
Operating Income-49,604
Net Interest Income3,694
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-46,049-53,159
EBIT - interestExpense = -51,105
-46,049
-44,548
Interest Expense1,501
Earnings Before Interest and Taxes (EBIT)-49,604-44,548
Earnings Before Interest and Taxes (EBITDA)-48,598
 
After tax Income (+$)
Income Before Tax-46,049
Tax Provision--34
Net Income From Continuing Ops-39,917-46,015
Net Income-46,049
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses77,065
Total Other Income/Expenses Net3,555-3,694
 

Technical Analysis of Zevra
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Zevra. The general trend of Zevra is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Zevra's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Zevra Therapeutics Inc..

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: .

The bearish price targets are: 7.8401 > 7.67 > 6.61.

Tweet this
Zevra Therapeutics Inc. Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Zevra Therapeutics Inc.. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Zevra Therapeutics Inc. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Zevra Therapeutics Inc.. The current macd is 0.28670641.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Zevra price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Zevra. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Zevra price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Zevra Therapeutics Inc. Daily Moving Average Convergence/Divergence (MACD) ChartZevra Therapeutics Inc. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Zevra Therapeutics Inc.. The current adx is 22.00.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Zevra shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Zevra Therapeutics Inc. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Zevra Therapeutics Inc.. The current sar is 8.05415656.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Zevra Therapeutics Inc. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Zevra Therapeutics Inc.. The current rsi is 67.47. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Zevra Therapeutics Inc. Daily Relative Strength Index (RSI) ChartZevra Therapeutics Inc. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Zevra Therapeutics Inc.. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Zevra price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Zevra Therapeutics Inc. Daily Stochastic Oscillator ChartZevra Therapeutics Inc. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Zevra Therapeutics Inc.. The current cci is 189.77.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Zevra Therapeutics Inc. Daily Commodity Channel Index (CCI) ChartZevra Therapeutics Inc. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Zevra Therapeutics Inc.. The current cmo is 44.42.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Zevra Therapeutics Inc. Daily Chande Momentum Oscillator (CMO) ChartZevra Therapeutics Inc. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Zevra Therapeutics Inc.. The current willr is -3.05572532.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Zevra Therapeutics Inc. Daily Williams %R ChartZevra Therapeutics Inc. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Zevra Therapeutics Inc..

Zevra Therapeutics Inc. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Zevra Therapeutics Inc.. The current atr is 0.51431228.

Zevra Therapeutics Inc. Daily Average True Range (ATR) ChartZevra Therapeutics Inc. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Zevra Therapeutics Inc.. The current obv is 18,928,877.

Zevra Therapeutics Inc. Daily On-Balance Volume (OBV) ChartZevra Therapeutics Inc. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Zevra Therapeutics Inc.. The current mfi is 60.30.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Zevra Therapeutics Inc. Daily Money Flow Index (MFI) ChartZevra Therapeutics Inc. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Zevra Therapeutics Inc..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-16STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-31DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-09ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-13BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-25WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.

6.3. Candlestick Patterns

Zevra Therapeutics Inc. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Zevra Therapeutics Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5067.475
Ma 20Greater thanMa 508.708
Ma 50Greater thanMa 1008.190
Ma 100Greater thanMa 2007.464
OpenGreater thanClose9.240
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Zevra with someone you think should read this too:
  • Are you bullish or bearish on Zevra? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Zevra? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Zevra Therapeutics Inc.

I send you an email if I find something interesting about Zevra Therapeutics Inc..


Comments

How you think about this?

Leave a comment

Stay informed about Zevra Therapeutics Inc..

Receive notifications about Zevra Therapeutics Inc. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.